Good MorningA weaker than expected jobs report lifted the market. The contrarian logic is that weakening employment numbers will give the Federal Reserve room to pause its campaign of raising interest rates.
However, after a strong rally to start the day, stocks closed the week slightly lower. Higher bond yields have been pushing buyers away from stocks.
This week was a net win for the bears. And it sets the stage for economic data coming in next week. Palantir will deliver its quarterly earnings on Monday which is expected to be a market moving report. Investors will also get more information about the direction of inflation when the consumer price index (CPI) and producer price index (PPI) are released.
These reports could point to a continued downward trend. But investors should be cautious, because it’s likely that rising oil prices are not yet priced in.
Featured: U.S. Loses to China in Shocking WAR GAMES (Behind the Markets) 
|
Stocks | | |
Natural gas is one of the world's most reliable energy sources due to its low prices and lower environmental impact, especially when compared with other nonrenewable energy sources like oil and coal.
It has become a key pillar of modern economies worldwide because it also serves as a clea... Read the Full Story |
|
From Our PartnersHe called the 2020 crash and 2022 bear market. Now he says the next 90 days will determine your financial life for a decade. It doesn't matter if you have money in stocks right now, or are waiting on the sidelines. The short period we're about to enter changes everything. | | | | Prepare here.. |
|
Stocks | | | Profits rebounded at Warren Buffett's conglomerate along with the value of its $353 billion stock portfolio in the second quarter to hit $35.9 billion, and many of Berkshire Hathaway's assorted businesses also performed well, led by strong results in its core insurance businesses, particularly Geico... Read the Full Story |
|
Markets | | |
Amgen Inc. (NASDAQ: AMGN) delivered a solid earnings report after the market closed on August 3. Shareholders hope the results will be enough to reverse the fortunes of AMGN stock, down 12% in 2023.
But heading into earnings, analyst sentiment suggests that all the growth may already b... Read the Full Story |
|
From Our PartnersIf that sounds too good to be true… trust me, I get it. But one trader has done just that, holding one of the top track records on Wall Street in recent years. Regardless of bull or bear markets, his 9/10 win rate has held strong (with no signs of slowing down).
Now he wants YOU to have the same opportunity to rack up incredible gains, no matter what the market does next. Still not convinced? | | Click HERE to see it with your own eyes. |
|
Stocks | | |
We don’t know how much relief most Americans are feeling from the effects of inflation, particularly at the grocery store. But we live in a data-driven world, and the data says that inflation is retreating on a year-over-year basis.
Still, inflation is growing above the Federal R... Read the Full Story |
|
Stocks | | | Stocks fell Friday to close out a rare losing week for Wall Street following mixed reports on the U.S. job market and two of the market's most influential stocks.The S&P 500 sank 23.86, or 0.5%, to 4,478.03. It was the fourth straight drop for Wall Street's main measure of health after it set a ... Read the Full Story |
|
From Our PartnersHi, this is 10 time trading champion Chuck Hughes and for a long time even I was missing out on the strategy that took my account to a whole new level…
In my new guide, "Hidden Income Strategy", I'll reveal exactly how you could use this unique strategy to earn more–starting now! | | Click here for a free copy today! |
|
Markets | | |
Shares of XPO (NYSE: XPO) have been on a stratospheric rise since the first quarter of 2023, blowing past all expectations and delivering a massive 165% advance in less than six months.
Some market participants speculate that this rally has run out of steam, but you can't fight th... Read the Full Story |
|
Markets | | |
Starbucks Corporation (NASDAQ: SBUX) share prices are at a turning point, and a breakout is imminent. The market has been consolidating at the low end of a trading range following a minor correction, but that episode is over.
The likely scenario is that upward price pressure will conti... Read the Full Story |
|
Markets | | | Banks from four Arab countries are interested in investing in Lebanon’s struggling banking sector, which was hard-hit by the small nation’s three-year economic meltdown, a top Arab banker said Thursday.Lebanon is in the throes of its worst economic crisis in its short and troubled history that has s... Read the Full Story |
|
Markets | | | Toshiba announced a 2 trillion yen ($14 billion) tender offer on Monday in a move that would take it private, as the scandal-tarnished Japanese electronics and energy giant seeks to turn itself around.The tender offer led by a buyout fund of major Japanese banks and companies called Japan Industrial... Read the Full Story |
|
Markets | | | Airbnb said Thursday its second-quarter profit jumped more than 70% over last summer, to $650 million, as revenue rose on strong bookings for summer-vacation rentals.The San Francisco company said bookings grew 11% over the same period last year. Still, they were a bit lighter than analysts expected... Read the Full Story |
|
Monday's Early Bird Stock Of The Day Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. | | View Today's Stock Pick |
|
